Trial intelligence / Profile preview

Enhanced efficacy of photodynamic therapy in combination with 5% imiquimod in non-melanoma skin cancer

2013-000092-33Phase 4Terminated

Sponsor: Medical University of Vienna
Start: Sep 2013
Modality: Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, randomised, single-blind trial of imiquimod in non-melanoma skin cancer (NMSC) and basal cell carcinoma (BCC) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Tumor clearance at 3 months. Started Sep 2013; status: terminated.

Drugs

imiquimod

Conditions

non-melanoma skin cancer (NMSC)basal cell carcinoma (BCC)

Beyond the preview

Go deeper on 2013-000092-33.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-000092-33.